The short version of lyophilised powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-06 and is reviewed periodically as new material appears.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
=== Early research === The ability of palladium to absorb hydrogen was recognized as early as the nineteenth century by Thomas Graham. In the late 1920s, two Austrian-born scientists, Friedrich Paneth and Kurt Peters, originally reported the transformation of hydrogen into helium by nuclear catalysis when hydrogen was absorbed by finely divided palladium at room temperature. However, the authors later retracted that report, saying that the helium they measured was due to background from the air. In 1927, Swedish scientist John Tandberg reported that he had fused hydrogen into helium in an electrolytic cell with palladium electrodes. On the basis of his work, he applied for a Swedish patent for "a method to produce helium and useful reaction energy". Due to Paneth and Peters's retraction and his inability to explain the physical process, his patent application was denied. After deuterium was discovered in 1932, Tandberg continued his experiments with heavy water. The final experiments made by Tandberg with heavy water were similar to the original experiment by Fleischmann and Pons. Fleischmann and Pons were not aware of Tandberg's work. The term "cold fusion" was used as early as 1956 in an article in The New York Times about Luis Alvarez's work on muon-catalyzed fusion. Paul Palmer and then Steven Jones of Brigham Young University used the term "cold fusion" in 1986 in an investigation of "geo-fusion", the possible existence of fusion involving hydrogen isotopes in a planetary core.
==== Season 1 ==== At the beginning of the series, the Roys gather to celebrate Logan's 80th birthday, where it is assumed he will step down as CEO and name Kendall as his successor. However, he shocks his family when he announces he will stay on as CEO and hands them documents naming Marcia as his chief trustee upon his death. Logan suffers a debilitating stroke later that day and is admitted to the hospital, where the rest of his family and inner circle debate how to steward the company while he is incapacitated. Logan soon recovers and announces at a gala event that he will remain CEO, but continues displaying erratic behavior. Kendall plots a vote of no confidence against his father along with Roman and several members of the company's senior management, but it ultimately fails, in part because Logan refuses to leave the room during the vote and instead berates several board members into siding with him, while firing everyone who voted for the motion (including Kendall). Over the following months, Logan remains at odds with his children: Shiv goes to work as a political consultant for presidential candidate Gil Eavis, a Democratic Senator who despises Logan and Waystar, while Kendall - a recovering addict - relapses and derails a family therapy session intended to allay public concerns over the company's stability. At Shiv's wedding, Logan learns that Kendall has plotted a hostile takeover of the company alongside his friend Stewy and Logan's nemesis Sandy Furness.
=== Neurological === Although the dermatological changes are the most obvious symptoms of Urbach–Wiethe disease, many patients also have neurological symptoms. About 50–75% of the diagnosed cases of Urbach–Wiethe disease also show bilateral symmetrical calcifications on the medial temporal lobes. These calcifications often affect the amygdala and the periamygdaloid gyri. The amygdala is thought to be involved in processing biologically relevant stimuli and in emotional long-term memory, particularly those associated with fear, and both PET and MRI scans have shown a correlation between amygdala activation and episodic memory for strongly emotional stimuli. Therefore, Urbach–Wiethe disease patients with calcifications and lesions in these regions may suffer impairments in these systems. These calcifications are the result of a buildup of calcium deposits in the blood vessels within this brain region. Over time, these vessels harden and the tissue they are a part of dies, causing lesions. The amount of calcification is often related to disease duration. The true prevalence of these calcifications is difficult to accurately state as not all patients undergo brain imaging. Some patients also exhibit epilepsy and neuropsychiatric abnormalities. Epilepsy symptoms could begin with light anxiety attacks and can be controlled with anti-epileptic medications. Other patients present with symptoms similar to schizophrenia while some suffer from mood, anxiety, and psychotic disorders.
Nicotinamide mononucleotide ("NMN" and "β-NMN") is a nucleotide derived from ribose, nicotinamide, nicotinamide riboside and niacin. In humans, several enzymes use NMN to generate nicotinamide adenine dinucleotide (NADH). In mice, it has been proposed that NMN is absorbed via the small intestine within 10 minutes of oral uptake and converted to nicotinamide adenine dinucleotide (NAD+ form) through the Slc12a8 transporter. However, this observation has been challenged, and the matter remains unsettled. Because NADH is a cofactor for processes inside mitochondria, for sirtuins and PARP, NMN has been studied in animal models as a potential neuroprotective and anti-aging agent. The alleged anti-aging effect at the cellular level by inhibiting mitochondrial decay in presence of increased levels of NAD+ makes it popular among anti-aging products. Dietary supplement companies have aggressively marketed NMN products, claiming those benefits. However, no human studies to date have properly proven its anti-aging effects with proposed health benefits only suggested through research done in vitro or through animal models. Single-dose administration of up to 500 mg was shown safe in men in a study at Keio University. One 2021 clinical trial found that NMN improved muscular insulin sensitivity in prediabetic women, while another found that it improved aerobic capacity in amateur runners. A 2023 clinical trial showed that NMN improves performance on a six-minute walking test and a subjective general health assessment.
Sources: en.wikipedia.org
For example, metro stations in Pyongyang, North Korea, were constructed 110 metres (360 ft) below ground, and were designed to serve as nuclear shelters in the event of war, with each station entrance built with thick steel blast doors. An example of privately funded fallout shelters is the Ark Two Shelter in Ontario, Canada, and autonomous shelters have been constructed with an emphasis on post-war networking and reconstruction. In Switzerland, the majority of homes have an underground blast and fallout shelter. The country has an overcapacity of such shelters and can accommodate slightly more than the nation's population size. While the nuclear fallout shelters described above are the ideal long-term protection methods against dangerous radiation exposure in the event of a nuclear catastrophe, it is also necessary to have mobile protection equipment for medical and security personnel to safely assist in containment, evacuation, and many other necessary public safety objectives which ensue as a result of nuclear detonation. There are many basic shielding strategies used to protect against the deposition of radioactive material from external radiation environments. Respirators that protect against internal deposition are used to prevent the inhalation and ingestion of radioactive material and dermal protective equipment which is used to protect against the deposition of material on external structures like skin, hair, and clothing.
== Awards == 1999 - March of Dimes Basil O’Connor Award 1999 - Frederick J. Terman Junior Faculty Award 1999 - Rita Allen Foundation Scholar 1999 - American Heart Association New Investigator Award 2000 - Cancer Research Institute New Investigator Award 2001 - Pew Scholar 2002 - Keck Distinguished Medical Scholar 2004 - Established Investigator of the American Heart Association 2012 - Elected to National Academy of Sciences 2013 - NIHMERIT award 2015 - Member of Mathematical Sciences Jury for the Infosys Prize 2016 - Elected to National Academy of Medicine 2024 - Passano Award
Calcitonin gene-related peptide 1 (CGRP1), also called calcitonin-related polypeptide alpha, is a hormone that in humans is encoded by the CALCA gene. This calcitonin gene-related peptide triggers vasodilation (relaxation/widening of blood vessels), and also signals to platelets.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.